Company intelligence / Profile preview

OS Therapies

Rockville, Maryland, United Statesostherapies.com ↗

Ownership: Public · OSTX
Employees: ~5
Development stage: Phase 2

Overview

OS Therapies’ lead candidate, OST-HER2, is a listeria-based off-the-shelf immunotherapy targeting HER2-expressing cancers. The company completed the treatment phase of a Phase 2b trial in recurrent, fully resected lung metastatic osteosarcoma with positive results and is preparing a Biologics License Application (BLA) submission to the FDA in 2025. The therapy has received rare pediatric disease designation and other regulatory incentives. Early safety data in breast cancer patients are also available. Their tunable ADC platform is advancing two new candidates.

Therapeutic areas: Oncology
Modalities: Cancer immunotherapy (listeria-based biologic)Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

6 assets

ADXS 31164

5 more assets in the full pipeline.

Request access →

Partnerships

Johnson & Johnson JLABS incubator participant

Financials

Market cap: $84.7M
Total revenue: $0
Enterprise value: $84.5M

Beyond the preview

Go deeper on OS Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OS Therapies.

Explore the full profile